Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

33.3%

3 terminated/withdrawn out of 9 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

33%

3 trials in Phase 3/4

Results Transparency

117%

7 of 6 completed trials have results

Key Signals

7 with results

Enrollment Performance

Analytics

Phase 2

3(33.3%)

Phase 1

3(33.3%)

Phase 3

3(33.3%)

9Total

Phase 2(3)

Phase 1(3)

Phase 3(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT05026177Phase 3Terminated

Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease

Role: lead

NCT05352763Phase 2Terminated

Open-Label Extension of the PTI-125-04 Study in Mild-to-Moderate Alzheimer's Disease

Role: lead

NCT04994483Phase 3Completed

Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease

Role: lead

NCT05575076Phase 3Terminated

Open-label Extension for Phase 3 Clinical Trials of Simufilam

Role: lead

NCT04388254Phase 2Completed

Simufilam (PTI-125), 100 mg, for Mild-to-moderate Alzheimer's Disease Patients

Role: lead

NCT06195319Phase 1Completed

Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-Simufilam Following a Single Oral Dose in Healthy Male Subjects

Role: lead

NCT06390410Phase 1Completed

A Pharmacokinetic Study of Simufilam in Subjects With Impaired Hepatic Function

Role: lead

NCT04932655Phase 1Completed

Food Effect and Bioequivalence Study of Simufilam Tablets in Healthy Volunteers

Role: lead

NCT04079803Phase 2Completed

PTI-125 for Mild-to-moderate Alzheimer's Disease Patients

Role: lead

All 9 trials loaded